News Headlines Article

Taking page from early AIDS activists, ALS patients push for access to experimental drug
San Francisco Business Times

A one-time tech security specialist, “Mike” now calls himself an amateur chemist and neurologist, seeking out new drugs to treat the deadly muscle-wasting disease known as amyotrophic lateral sclerosis. It’s not a hobby; it’s his life. Diagnosed in October 2013 with ALS — or Lou Gehrig’s disease — the 55-year-old Massachusetts resident believes he’s found hope in an experimental drug under development by a small Palo Alto company.

Commands